Future studies are needed to test and refine the “TAR11” signature and assess whether enhanced PKCα activity, in particular, plays a significant role in the genesis and/or maintenance of skin lesions in disorders such as PSOR, HS, AD, and others. Here, PRKCA is linked to Alzheimer disease.